Y Intercept Hong Kong Ltd Grows Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Y Intercept Hong Kong Ltd boosted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 269.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,721 shares of the specialty pharmaceutical company's stock after buying an additional 7,090 shares during the period. Y Intercept Hong Kong Ltd's holdings in Jazz Pharmaceuticals were worth $1,207,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Fuller & Thaler Asset Management Inc. lifted its stake in Jazz Pharmaceuticals by 117.4% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock worth $115,681,000 after purchasing an additional 507,234 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in Jazz Pharmaceuticals in the fourth quarter worth $59,668,000. Perpetual Ltd lifted its stake in Jazz Pharmaceuticals by 60.2% in the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after purchasing an additional 357,784 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after purchasing an additional 320,724 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after purchasing an additional 315,608 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the transaction, the chief executive officer directly owned 439,307 shares in the company, valued at $51,113,369.45. The trade was a 0.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Seamus Mulligan bought 100,000 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the purchase, the director owned 100,000 shares in the company, valued at approximately $9,826,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 2,500 shares of company stock valued at $277,930. Company insiders own 4.30% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on JAZZ. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Robert W. Baird lowered their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price objective on the stock. Finally, Morgan Stanley decreased their price objective on shares of Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 22nd. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $181.64.

Jazz Pharmaceuticals Stock Down 1.0%

Shares of Jazz Pharmaceuticals stock traded down $1.16 on Monday, reaching $117.07. The stock had a trading volume of 50,905 shares, compared to its average volume of 966,491. The company has a 50 day moving average price of $110.22 and a 200 day moving average price of $118.04. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The stock has a market capitalization of $7.08 billion, a P/E ratio of 15.65, a P/E/G ratio of 5.69 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm's revenue for the quarter was down .5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.68 EPS. As a group, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.